Oriptan (Sumatriptan)

Sumatriptan selectively activates 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. This causes vasoconstriction of dilated intracranial arteries and blocks the release of inflammatory neuropeptides, interrupting the pain pathway that triggers migraine and cluster headaches.

The prescribed dose of Oriptan is determined by the treating physician based on the patient’s clinical condition, age, and medical history. Dosage instructions are individualized and should be followed exactly as written on the prescription label.

Oriptan should be used during pregnancy or while breastfeeding only if clearly needed and after a risk‑benefit assessment by a healthcare professional. Limited data are available, so clinicians generally reserve its use for situations where alternative therapies are unsuitable.

To order Oriptan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Oriptan (sumatriptan) belongs to the triptan class, which offers rapid, targeted relief for acute migraine and cluster headaches. Compared with non‑specific analgesics, triptans provide higher efficacy for migraine pain and associated symptoms, but they require caution in patients with cardiovascular disease.

Store Oriptan tablets at ambient temperature below 25 °C, in the original blister pack, protected from moisture and direct sunlight. Keep the medication out of reach of children and do not use it after the expiry date printed on the packaging.

Oriptan is taken orally as a tablet. The patient swallows the tablet whole with water, typically at the onset of migraine or cluster headache symptoms. If needed, a second dose may be taken after a specified interval, as directed by the prescribing clinician.

Serious risks include coronary vasospasm, myocardial ischemia, severe hypertension, and serotonin syndrome, especially when combined with other serotonergic agents. Patients should seek immediate medical attention if they experience chest pain, severe headache, or any signs of an allergic reaction.

Oriptan is contraindicated in individuals with uncontrolled cardiovascular disease, recent myocardial infarction, severe hepatic or renal impairment, known hypersensitivity to sumatriptan, and in children under 12 years of age. It should also be avoided in patients taking MAO inhibitors or other triptans.